These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 2876402)

  • 1. [Considerations on the use of long-acting neuroleptics in a mental health center].
    Carotti P; Merli R
    Minerva Med; 1986 Sep; 77(34-35):1577-83. PubMed ID: 2876402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Trial at the guidance center of ixelles of a major neuroleptic drug: anatensol decanoate].
    Berliner J
    Acta Psychiatr Belg; 1974 May; 74(3):305-16. PubMed ID: 4455024
    [No Abstract]   [Full Text] [Related]  

  • 3. Experience with fluphenazine decanoate in the management of chronic schizophrenic outpatients.
    Gaby N; Lefkowitz D; Israel JR
    N C Med J; 1982 Sep; 43(9):641-4. PubMed ID: 6958987
    [No Abstract]   [Full Text] [Related]  

  • 4. Differential study of 2 long-acting neuroleptics, fluphenazine enanthate and pipothiazine undecylenate.
    Gayral LF; Escande MM; Fournie HC; Huron RJ
    Therapie; 1973; 28(3):611-25. PubMed ID: 4771904
    [No Abstract]   [Full Text] [Related]  

  • 5. [Long-acting neuroleptic preparations and their use in mental disorders].
    Vovin RIa; Vovina EN
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1972; 72(6):920-4. PubMed ID: 5050052
    [No Abstract]   [Full Text] [Related]  

  • 6. The pharmacist's role in team treatment of patients receiving injectable long-acting fluphenazine.
    Giles RE
    Hosp Pharm; 1976 Oct; 11(10):404, 407-8. PubMed ID: 1028808
    [No Abstract]   [Full Text] [Related]  

  • 7. [Treatment of therapeutically resistant paranoid schizophrenic patients with Moditen-depot combined with other psychotropic drugs and Leponex].
    Gamburg AL; Aranovich AG; Kotel'kevich IuN; Omorokov BM; Rasniuk VA
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1980; 80(8):1211-6. PubMed ID: 6111169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparison between the effectiveness of fluphenazine decanoate and oxyprothepin decanoate in schizophrenia (double-blind crossover study)].
    Balon R; Kabesh Ia; Papezhova G
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1982; 82(1):116-8. PubMed ID: 6121437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Characteristics of the psychotropic activity of long-acting drugs (experience in the use of Moditen-depot)].
    Smulevich AB; Minsker EI; Mazaeva NA; Volkova RP; Lukanina SK
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1972; 72(6):912-20. PubMed ID: 5050051
    [No Abstract]   [Full Text] [Related]  

  • 10. [Comparative study of delayed-action neuroleptics in psychiatric therapeutics].
    Pellet J; Guyotat J; Marie-Cardine M; Dubor P; Favre-Tissot M; Caron F; Cottraux J
    J Med Lyon; 1972 Apr; 53(227):591-8. PubMed ID: 4404295
    [No Abstract]   [Full Text] [Related]  

  • 11. Suicidal risk in the treatment of outpatient schizophrenics with long-acting neuroleptics.
    Niturad A; Nicholschi-Oproiu L
    Agressologie; 1978; 19(C):145-8. PubMed ID: 35993
    [No Abstract]   [Full Text] [Related]  

  • 12. The risk/benefit ratio of depot neuroleptics: a Scandinavian perspective.
    Dencker SJ
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):22-7. PubMed ID: 6143744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical and ambulatory experiences with fluphenazine decanoate lyogen depot in prolonged therapy of psychiatric disorders].
    Moldenhauer B
    Med Welt; 1970 Jun; 25():1150-4. PubMed ID: 5512636
    [No Abstract]   [Full Text] [Related]  

  • 14. [Prophylactic efficacy of long-acting vs. short-acting neuroleptics in schizophrenic out-patients (author's transl)].
    Tegeler J; Lehmann E; Stockschlaeder M
    Nervenarzt; 1980 Nov; 51(11):654-61. PubMed ID: 6109262
    [No Abstract]   [Full Text] [Related]  

  • 15. [What should we recommend for schizophrenic patients: long-term drug prevention or interval treatment?].
    Müller P
    Nervenarzt; 1983 Sep; 54(9):477-85. PubMed ID: 6138720
    [No Abstract]   [Full Text] [Related]  

  • 16. [Indications for long-acting neuroleptics].
    Maillard M; Tholose A
    Ann Med Psychol (Paris); 1980 Mar; 138(3):370-5. PubMed ID: 6111970
    [No Abstract]   [Full Text] [Related]  

  • 17. [Characteristics of the therapeutic action fluphenzaine decanoate (moditen-depot) in schizophrenia].
    Tsutsul'kovskaia MIa; Minsker EI; Panteleeva GP; Mazurskii MB; Pekunova LG
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1973; 73(5):753-8. PubMed ID: 4718619
    [No Abstract]   [Full Text] [Related]  

  • 18. [Comparative studies of the effects of perazine, fluphenazine, trifluoperazine, chlorpromazine and haloperidol on primary and deficit symptoms of paranoid schizophrenia].
    Termińska K; Mrowiec W
    Psychiatr Pol; 1989; 23(1):24-30. PubMed ID: 2573098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of prolonged-action neuroleptics on rehospitalization of psychotic patients in a regional practice].
    Richou H
    Ann Med Psychol (Paris); 1975 Jul; 2(2):399-402. PubMed ID: 9894
    [No Abstract]   [Full Text] [Related]  

  • 20. Practical considerations in the use of depot neuroleptics for the treatment of schizophrenia.
    Johnson DA
    Br J Hosp Med; 1977 Jun; 17(6):546-58. PubMed ID: 18242
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.